Agnès Gouble

TL;DR: The applicability of TALEN-mediated genome editing to a scalable process enables the manufacturing of third-party CAR T-cell immunotherapies against arbitrary targets and can therefore be used in an "off-the-shelf" manner akin to other biologic immunopharmaceuticals.

TL;DR: In this paper, custom-made meganucleases, which recognize and cleave a specific nucleotide sequence, derived polynucleotide sequences, recombinant vector cell, animal, or plant comprising said polyn nucleotide sequences are used for genetic engineering, antiviral therapy and gene therapy.

TL;DR: Tailored I- CreI derivatives cleaving sequences from the XPC gene were found to induce high levels of gene targeting, similar to the I-CreI scaffold or theI-SceI "gold standard", the first time an engineered homing endonuclease has been used to modify a chromosomal locus.

TL;DR: Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and its application for genome engineering and gene therapy as discussed by the authors.

TL;DR: This article used rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells.